CLINICAL RESPONSES OF SARILUMAB BASED ON RHEUMATOID FACTOR AND ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY STATUS IN PATIENTS WITH RHEUMATOID ARTHRITIS